Real-world data is only as valuable as what you do with it. The challenge in 2026 is no longer data scarcity — it is knowing how to access the right data sources, apply rigorous analytical methods, meet regulatory standards, and translate findings into decisions that move products forward.

For pharma and life sciences professionals working in RWD, analytics, and evidence generation, the conference calendar reflects that shift. Events are no longer just about awareness of RWE as a concept. They are where methodological debates get resolved, analytical tools get stress-tested, and regulatory expectations get clarified — in person, with the people who set and use those standards.

Below are ten leading pharma events for real-world data, analytics, and evidence generation in 2026.

TL;DR — 10 Leading Pharma Events for Real-World Data, Analytics & Evidence Generation (2026)

The 10 Leading Pharma Events for Real-World Data, Analytics & Evidence Generation

Let’s walk through each leading pharma event for real-world data, analytics and evidence generation in depth.

1. RWE Connect 2026 (14–15 October 2026, Boston, USA)

Best dedicated forum for real-world data platforms, analytics innovation, and evidence strategy

RWE Connect 2026 is the strongest single-event option for professionals whose work sits at the intersection of real-world data, analytics, and evidence generation. Organised by Convolign, the conference brings together 150+ attendees and 40+ speakers across two days in Boston — one of the world’s most active life sciences and digital health ecosystems.

The programme is built around three integrated themes: regulatory science, data and analytics, and technology and innovation. For data and analytics professionals specifically, this means sessions covering AI and machine learning in evidence generation, data interoperability across EHRs and registries, synthetic control arms, digital endpoints, decentralised study approaches, and patient-reported outcomes platforms.

The speaker lineup reflects the depth of engagement available. Heads of RWE from Boehringer Ingelheim, Gilead Sciences, and BioMarin are joined by data science and analytics leaders from Arcadia, Forian, and Truveta — organisations working daily on the infrastructure and platforms that make real-world data usable for regulatory and commercial purposes.

Beyond the formal sessions, an RWE Innovation Showcase highlights cutting-edge methodologies and tools. A Startup Pavilion spotlights next-generation analytics companies. Hands-On Masterclass Workshops provide practical, facilitator-led instruction in study design, data interoperability, and analytical approaches applicable to current projects.

Who should attend:

• Data science and analytics professionals in pharma and biotech
• RWE and evidence generation leads
• Medical affairs and regulatory professionals engaging with RWD
• Technology providers, CROs, and RWD platform companies

2. ISPOR 2026 (17–20 May 2026, Philadelphia, USA)

Best for HEOR methods, AI integration in evidence generation, and value framework professionals

ISPOR 2026 in Philadelphia focused heavily on how analytical methods are evolving — particularly the role of AI in systematic literature reviews, evidence synthesis, HEOR workflows, and real-world study design. Sessions addressed AI governance, predictive modelling, and the methodological requirements for AI-generated evidence to be accepted by payers and HTA bodies.

For professionals working at the technical edge of evidence generation, ISPOR offers short courses, poster sessions, and issue panels with a density of methodological content that is difficult to match elsewhere.

Strengths: Scientific rigour, AI and methods depth, global HEOR community.

Considerations: Broad programme; data and analytics sessions require advance session planning.

3. HTAi 2026 Annual Meeting (6–10 June 2026, Istanbul, Turkey)

Best for understanding how HTA bodies evaluate real-world data for access decisions

For evidence generation professionals, the value of HTAi lies in direct access to the people and processes that determine whether real-world evidence is accepted for access decisions. The 2026 meeting in Istanbul addressed how HTA bodies assess study design, data quality, and evidence credibility, including AI-enabled digital health technologies and digital endpoints.

Understanding what constitutes fit-for-purpose evidence from the HTA perspective is one of the most practically valuable outcomes of attending this event.

Strengths: HTA body access, evidence evaluation standards, policy and methods crossover.

Considerations: Scientific and policy focus; limited commercial and vendor engagement.

4. GetReal Institute Annual Conference 2026 (29–30 June 2026, Utrecht, Netherlands)

Best for European RWD methodology, data quality standards, and regulatory/HTA alignment

The GetReal Institute annual conference is the most rigorous European forum for working through the practical challenges of generating fit-for-purpose real-world evidence. The 2026 edition in Utrecht addressed data quality assurance, common data models, external control arm methodology, and the role of AI in RWD analysis — examined against the expectations of European regulators and HTA bodies.

The European Health Data Space regulation and the EU HTA Regulation were central to programme discussions, making this the most relevant European event for teams developing evidence strategies aimed at EMA or joint clinical assessment submissions.

Strengths: Methodological depth, European regulatory alignment, multistakeholder design.

Considerations: Smaller scale; non-commercial format.

5. ISPE 42nd Annual Meeting / ICPE 2026 (29 August–2 September 2026, Milan, Italy)

Best for pharmacoepidemiology methods, causal inference, and drug safety evidence

ICPE 2026 at the Allianz MiCo Convention Center in Milan is the premier scientific gathering for pharmacoepidemiology — the discipline that underpins most real-world observational study design. Sessions cover causal inference methods, study design for regulatory purposes, target trial emulation, propensity score methods, confounding control, and post-market safety evidence.

For data scientists and RWE researchers working on the methodological backbone of evidence generation, ICPE is one of the most technically dense events of the year.

Strengths: Methodological rigour, causal inference focus, RWD science depth, regulatory crossover.

Considerations: Academic orientation; attendance is best suited to methods-focused professionals.

6. 14th IMPACCT Real-World Evidence Summit (October 2026, Boston, USA)

Best for pharma teams working on data quality, AI-driven RWE, and lifecycle integration

The IMPACCT summit consistently centres its programme on applied questions — not what RWE could theoretically do, but how leading pharma organisations are actually doing it. Past sessions have addressed data standardisation and quality assurance, validation of AI and predictive models in RWE analysis, external control arm construction, and regulatory submission strategies using real-world data.

The 14th edition in October 2026 will build on prior focus areas as CMS guidance and FDA’s RWE Centre announcements continue to shape what is expected of real-world data studies.

Strengths: Applied case studies, senior pharma practitioners, data quality focus.

Considerations: Specific dates and venue TBC.

7. DIA Real-World Evidence Conference 2026 (19–20 October 2026, North Bethesda, USA)

Best for professionals working on regulatory-ready real-world data and governance

The DIA’s 2026 RWE Conference brings regulatory science to the centre. Speakers from the FDA, EMA, and other global agencies join industry experts to address how regulatory standards for real-world data quality, governance, and study design are evolving — and what “decision-grade” evidence actually requires in a submission context.

Case studies and collaborative discussions make this a practical event for teams developing or refining regulatory-grade RWE programmes.

Strengths: Agency engagement, regulatory standards, data governance, governance frameworks.

Considerations: Two-day, targeted format; primarily valuable for regulatory and submission-focused teams.

8. ISPOR Healthcare Investment Summit 2026 (22–23 September 2026, San Francisco, USA)

Best for evidence professionals building the commercial case for RWD investment

The ISPOR Healthcare Investment Summit creates an unusual but valuable intersection: health economists, evidence generation professionals, and life sciences investors discussing how the quality and robustness of real-world data shapes product value and access outcomes. For teams building the business case for RWE infrastructure investment or articulating the value of robust RWD platforms to commercial leadership, this summit offers a commercially framed argument with HEOR depth.

Strengths: Investment-oriented framing, commercial evidence strategy, HEOR meets capital.

Considerations: Limited scientific programme; best for commercially oriented evidence leads.

9. ISPOR Europe 2026 (8–11 November 2026, Vienna, Austria)

Best for European pharma teams integrating RWE into market access and HTA programmes

ISPOR Europe 2026 in Vienna is the largest HEOR event in Europe, with 5,000+ attendees expected across research, industry, payer, and regulatory communities. The programme covers real-world evidence generation and application, with specific attention to European HTA regulation, joint clinical assessments, and the methodological requirements for evidence acceptable to European payers.

Strengths: European access community, HTA methods, payer engagement, scale.

Considerations: RWE is one stream within a large, multidisciplinary programme.

10. GlobalBSG Pharma Pricing & Market Access Innovation Summit (12–13 November 2026, Vienna, Austria)

Best for commercial teams connecting real-world outcomes evidence to pricing and access strategy

The GlobalBSG summit addresses how evidence from real-world studies supports outcomes-based contracting, managed entry agreements, and international access negotiations. For evidence generation teams whose work must ultimately support pricing and reimbursement decisions, this summit provides the commercial context that connects data to access outcomes.

Strengths: Senior commercial audience, access, and pricing integration.

Considerations: Limited scientific content; framed around the commercial application of evidence.

Choosing the Right Events

Not every event serves the same purpose. Scientific methods conferences, regulatory forums, and commercial strategy summits each deliver different value. The most effective approach to the 2026 calendar combines a primary event with cross-functional depth — and at least one event that challenges your analytical assumptions with external perspectives.

Register for RWE Connect 2026 in Boston, 14–15 October →